Synthetic Genomics, Inc. and Advaxis, Inc. have completed development and deployment of the first cGMP synthetic biology facility for the production of synthetic DNA constructs.
Synthetic Genomics has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics' proprietary replicon RNA technology toward th